|Preferred IUPAC name
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||500.607 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Adavosertib (development codes AZD1775, MK-1775) is an experimental anti-cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca. It is being investigated as a treatment for pancreatic cancer with phase 1 trial. University of Michigan researchers are as of 2019 planning a phase 2 study.
- "NCI Drug Dictionary". National Cancer Institute. 2 February 2011. Retrieved 17 August 2019.
- "AZD1775 | AstraZeneca Open Innovation". openinnovation.astrazeneca.com. Retrieved 17 August 2019.
- "Early Activity in Pancreatic Cancer With New Drug". www.medpagetoday.com. 16 August 2019. Retrieved 17 August 2019.
- Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, et al. (October 2019). "Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer". Journal of Clinical Oncology. 37 (29): 2643–2650. doi:10.1200/JCO.19.00730. PMC 7006846. PMID 31398082.
- "AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival". FierceBiotech. Retrieved 17 August 2019.